Navigation Links
Phase 3 Cystic Fibrosis Trial Results Presented at European Conference
Date:6/15/2009

c microorganisms between treatment groups, confirming that Bronchitol does not contribute to the bacterial load in the lung.

Bronchitol has received Orphan Drug Designation and fast track status for cystic fibrosis from the U.S. Food and Drug Administration and Orphan Drug Designation from the European Medicines Agency.

A more detailed account of the results of the trial are planned to be presented at the North American Cystic Fibrosis conference in Minneapolis in October.

Forward-Looking Statements

The statements contained in this media release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential for Aridol and/or Bronchitol. All forward-looking statements included in this media release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. We can not guarantee that any product candidate will receive FDA or other regulatory approval or that we will seek any such approval. Factors that could cause or contribute to such differences include, but are not limited to, factors discussed in the "Risk Factors and Other Uncertainties" section of our Form 20-F lodged with the U.S. Securities and Exchange Commission.

    CONTACT:

     Alan Robertson
     Chief Executive Officer
     Tel:   +61-2-9454-7200
     Email: alan.robertson@pharmaxis.com.au

    RELEASED THROUGH:

     Australia:
     Felicity Moffatt
     Tel:   +61-418-677-701
     Email: '/>"/>
SOURCE Pharmaxis Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
6. Phase III Trial Finds Pharmaxis Bronchitol Effective
7. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
8. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
9. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
10. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
11. Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
(Date:12/22/2014)... 22, 2014 Fertility Associates of Memphis ... Bank USA , a network of more than 20 ... partnership, patients have fast access to a national pool ... IVF . Fertility Associates of Memphis is the only ... treatment option. , Dr. William Kutteh , director ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one ... of Nick Maroulis, Pharm.D. to the newly created position ... In this position, Dr. Maroulis will continue to manage ... of our multi-site pharmacies as the company expands. Dr. ... that time he has served in many different capacities ...
(Date:12/19/2014)... Dec. 19, 2014 Bina Technologies, Inc. (Bina, ... that they have been acquired by Roche (SIX: RO, ... privately held company that provides a big data platform ... (NGS) data for the academic and translational research markets. ... and will continue to focus on development of their ...
Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... , , SUNRISE, Fla., July 28 ... delivering intelligent devices and biologics that help monitor, diagnose and treat ... cleared a phase I clinical trial for MyoCell SDF-1 (Stromal Derived ... trial will enroll 15 patients in a multicenter, randomized, dose escalation ...
... , , , ... CYNO ), a leading developer and manufacturer of a broad array of ... June 30, 2009. , , Second Quarter 2009 Financial ... June 30, 2009 were $20.8 million, compared with $39.2 million in the same ...
... BIRMINGHAM, Ala., July 28 BioCryst Pharmaceuticals (Nasdaq: ... financial results will be released on Thursday, July 30, 2009. ... at 11:00 a.m. Eastern Time to discuss the financial results ... call will be led by Jon P. Stonehouse, President and ...
Cached Biology Technology:United States FDA Clears the REGEN Trial to Test Bioheart's Combination Gene and Stem Cell Therapy in Heart Failure Patients 2United States FDA Clears the REGEN Trial to Test Bioheart's Combination Gene and Stem Cell Therapy in Heart Failure Patients 3United States FDA Clears the REGEN Trial to Test Bioheart's Combination Gene and Stem Cell Therapy in Heart Failure Patients 4Cynosure Reports Second Quarter 2009 Financial Results 2Cynosure Reports Second Quarter 2009 Financial Results 3Cynosure Reports Second Quarter 2009 Financial Results 4Cynosure Reports Second Quarter 2009 Financial Results 5Cynosure Reports Second Quarter 2009 Financial Results 6Cynosure Reports Second Quarter 2009 Financial Results 7Cynosure Reports Second Quarter 2009 Financial Results 8Cynosure Reports Second Quarter 2009 Financial Results 9Cynosure Reports Second Quarter 2009 Financial Results 10Cynosure Reports Second Quarter 2009 Financial Results 11Cynosure Reports Second Quarter 2009 Financial Results 12Cynosure Reports Second Quarter 2009 Financial Results 13BioCryst Pharmaceuticals to Announce Second Quarter 2009 Financial Results on July 30, 2009 2
(Date:12/19/2014)... , Dec. 18, 2014 Research and ... the addition of the "iPhone 5S Fingerprint ... Report" report to their offering. ... the acquisition of AuthenTec in July 2012, Apple ... 5S. It is currently the only device of ...
(Date:12/17/2014)... Dec. 15, 2014 The Defense Logistics ... easier to detect and prevent counterfeit microcircuits from ... the agency started performing an in-house microcircuit anti-counterfeit ... the authenticity of purchased microcircuits while increasing their ... control measures will be conducted at DLA,s Electronics ...
(Date:12/15/2014)... Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ... "Global Facial Recognition Market 2015-2019" report to ... Facial recognition is a technology ... system measures the overall facial feature of a ... the distance between eyes. Facial recognition is used ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... Conn.Paleontologists have discovered that a group of remarkable ancient ... much larger sizes than previously thought, thanks to extraordinarily ... as anomalocaridids, were already thought to be the largest ... Explosion" that saw the sudden appearance of all the ...
... Whale sharks ( Rhincodon typus ) are often thought to ... ocean. Scientists at the Smithsonian Institution and colleagues, however, have ... whale sharks can be gregarious and amass in the hundreds ... whale sharks have been witnessed in the past, ranging from ...
... board feet of softwood logs and 224.9 million board feet ... and Alaska in January, February, and March of this year, ... Station. "The volume of softwood log exports was up ... quarter of 2010, while the volume of softwood lumber exports ...
Cached Biology News:Scientists discover fossil of giant ancient sea predator 2Scientists discover the largest assembly of whale sharks ever recorded 2West coast's log, lumber exports increase in first quarter of 2011 2West coast's log, lumber exports increase in first quarter of 2011 3
... PCR carry-over contamination, which prevents false ... products from previous PCR amplifications without ... improves amplification ,Optimized for use with ... instrument systems , The GeneAmp PCR ...
... that catalyzes the hydrolysis of,starch to ... dextrins. The,level of a-amylase in various ... of,clinical significance in the diagnosis of ... and microbial a-amylases are,important enzymes for ...
... Labsystems Wellmix is a high-quality four-place microplate ... The shaking speed is adjustable from 100 ... speed and a small orbit ensure effective ... time is quick and easy to set ...
Rabbit polyclonal to STUB1 ( Abpromise for all tested applications). entrezGeneID: 10273 SwissProtID: Q9UNE7...
Biology Products: